SATISFY-JP: Satralizumab Improves PVR in Patients With PAH, With Yuichi Tamura, MD, PhD

Satralizumab, an investigational anti-interleukin-6 (IL-6) receptor antibody, improved pulmonary vascular resistance in patients with pulmonary arterial hypertension (PAH) at 24 weeks during the SATISFY-JP trial.¹

Presented at the American Heart…